Q/C TECHNOLOGIES, INC.
QCLSNasdaqHealthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$9.8M | −$10.2M | −$17.1M | −$15.3M | −$28.8M | −$9.5M |
| Net income | −$11.6M | −$23.4M | −$4.0M | −$15.2M | −$29.9M | −$9.5M |
| Total assets | $41.2M | $21.4M | $17.9M | $17.5M | $24.8M | $676,697 |
| Total liabilities | $16.4M | $6.7M | $5.1M | $2.8M | $1.2M | $5.9M |
| Equity | $21.8M | $9.8M | $12.4M | $14.7M | $23.6M | −$5.3M |
| EPS (diluted) | $-8.66 | $-11.15 | $-5.33 | $-11.74 | $-0.85 | — |
| Shares out. | 10.1M | 2.2M | 39.5M | 38.1M | 16.7M | 2.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −53.5%
- Return on assets
- −28.2%
- Return on capital (ROCE)
- −27.6%
- Liabilities / assets
- 39.9%
- Debt / equity
- 0.76×
- Book value / share
- $2.15
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -9.87distress
- Accruals / assets
- −6.2%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Qmissed a reporting deadline ↗May 18, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Pharmacyte Biotech, Inc.Activist (13D)Nov 18, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 2.4 | +30.4% |
| Apr 30, 2026 | 1.3M | 3.3 | +2.1% |
| Apr 15, 2026 | 1.3M | 4.2 | -9.8% |
| Mar 31, 2026 | 1.4M | 2.2 | -2.4% |
| Mar 13, 2026 | 1.5M | 1.0 | +39.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Changed auditorMar 13, 2026
- Entered a material agreement · Director / officer change · Other material eventJan 23, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventDec 9, 2025
- Director / officer change · Shareholder voteNov 14, 2025
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Director / officer changeOct 3, 2025
- Amended charter or bylaws · Regulation FD disclosureSep 26, 2025
- Entered a material agreement · Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureSep 10, 2025
- Entered a material agreement · Terminated a material agreement · Unregistered equity sale · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Regulation FD disclosureSep 2, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.